Nosocomial infections also referred to as healthcare-associated infections (HAI), are infection(s) acquired during the process of receiving health care that was not present during the time of admission. They may occur in different areas of healthcare delivery, such as in hospitals, long-term care facilities, and ambulatory settings, and may also appear after discharge. HAIs also include occupational infections that may affect staff.
Infection occurs when pathogen(s) spread to a susceptible patient host. In modern healthcare, invasive procedures and surgery, indwelling medical devices, and prosthetic devices are associated with these infections. The etiology of HAI is based on the source or type of infection and the responsible pathogen, which may be bacterial, viral, or fungal.
HAI is the most common adverse event in health care that affects patient safety. They contribute to significant morbidity, mortality, and financial burden on patients, families, and healthcare systems. The emergence of multi-drug resistant organisms is another complication seen with HAI. HAI affects 3.2% of all hospitalized patients in the United States, 6.5% in the European Union/European Economic Area, and worldwide prevalence is likely much higher. The burden of HAIs worldwide is unknown owing to the lack of surveillance systems for HAIs. However, there has been a great effort by infection prevention and control programs to develop surveillance systems and infection control methods.
Types of Healthcare-Associated Infection (HAI)
Responsible pathogens originate from a variety of different sources and are represented by different types of HAI. The Centers for Disease Control and Prevention broadly categorizes the types of HAI as follows:
Other types of HAI include non-ventilator-associated hospital-acquired pneumonia (NV-HAP), gastrointestinal infections (including Clostridioides difficile), other primary bloodstream infections—not associated with central catheter use, and other urinary tract infections—not associated with catheter use. HAI may also be grouped by affected systems such as ear, eye, nose and throat infections, lower respiratory tract infections (including bronchitis, tracheobronchitis, bronchiolitis, tracheitis, lung abscess or empyema without evidence of pneumonia), skin and soft-tissue infections, cardiovascular infection, bone and joint infections, central nervous systems infection, and reproductive tract infections.
A point-prevalence survey conducted in the United States in 2015 showed that the most common HAI in acute hospital settings is pneumonia, followed by gastrointestinal infections, SSI, other infections of the systems, as mentioned earlier, bloodstream infections, and urinary tract infections. The prevalence of these types of infections has changed from point-prevalence surveys in 2011, which showed pneumonia (21.8%) and SSI (21.8%) as the most common, followed by gastrointestinal (17.1%), urinary tract (12.9%), bloodstream (9.9%) and other infections. Interestingly, this same study showed that NV-HAP is the most common type of HAI in the acute health care setting, which is consistent with studies conducted in Europe.
Pathogens responsible for nosocomial infections include bacteria, viruses, and fungi. Specific microorganisms have unique characteristics that favor particular types of infections in susceptible hosts. The prevalence of infections caused by particular microorganisms varies depending on the healthcare facility location, healthcare setting, and patient population. Overall, bacteria are the most common pathogens, followed by fungi and viruses.
Bacteria may originate from an exogenous or endogenous source as part of the natural flora. Opportunistic bacterial infections occur when there is a breakdown of the host immune system functions. Common Gram-positive organisms include coagulase-negative Staphylococci, Staphylococcus aureus, Streptococcus species, and Enterococcus species (e.g. faecalis, faecium). Of all HAI associated pathogens, C.difficile accounts for the most commonly reported pathogen in US hospitals (15% of all infections with a reported pathogen). Common Gram-negative organisms include species of the Enterobacteriaceae family, including Klebsiella pneumoniae and Klebsiella oxytoca, Escherichia coli, Proteus mirabilis, and Enterobacter species; Pseudomonas aeruginosa, Acinetobacter baumanii, and Burkholderia cepacian. Acinetobacter baumanii is associated with high mortality within the intensive care setting owing to its inherent multi-drug resistant properties.
Multidrug-resistant bacteria are commonly seen in HAI and are associated with significant mortality. One study found that approximately 20% of all reported pathogens show multidrug-resistant patterns. Notorious pathogens include methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-intermediate Staphylococcus aureus (VISA) and Vancomycin-resistant Staphylococcus aureus (VRSA), Enterobacteriaceae with extended-spectrum cephalosporin resistance consistent with extended-spectrum beta-lactamase (ESBL) production, vancomycin-resistant Enterococcus (VRE), carbapenem-resistant Enterobacteriaceae and Acinetobacter species, and multi-drug resistant Pseudomonas aeruginosa.
Fungal pathogens are usually associated with opportunistic infections in immunocompromised patients and those with indwelling devices, such as central lines or urinary catheters. Candida species, such as C. albicans, C. parapsilosis, C.glabrata are the most commonly encountered fungal organisms associated with HAI. Candida auris poses a serious problem as a globally emerging multidrug-resistant organism with high morbidity and mortality due to difficulty with diagnoses and high rates of treatment failure. Altogether, Candida species make up the fourth most common pathogen across all types of HAIs. Aspergillus fumigatus may be acquired by airborne environmental contamination in areas of healthcare construction. However, infected hospitalized patients may be a primary source.
Infections due to viral pathogens are the least reported, making up 1-5% of all HAIs pathogens. Healthcare-acquired hepatitis B and C and human deficiency virus (HIV) has been implicated in unsafe needle practices. Globally 5.4% of all HIV infections are healthcare-associated and frequently occur in developing countries. Other reported viral pathogens include rhinovirus, cytomegalovirus, herpes simplex virus, rotavirus, and influenza.
Nosocomial infections affect a substantial number of patients globally, leading to increased mortality and financial impact on healthcare systems. While the actual global burden of healthcare-associated infection (HAI) remains unknown due to the lack of reliable data and surveillance systems, epidemiologic studies from Europe and the United States show relatively consistent results in surveillance programs. As such, most of the epidemiologic studies come from the United States and Europe.
Among European hospitals, the prevalence of at least one HAI varied based on the care setting: 4.4% in primary care hospitals; 7.1% in tertiary care hospitals; 19.2% in intensive care units; and 3.7% in long-term care facilities. It is determined that approximately 8.9 million distinct HAI episodes occur annually in acute care and long-term health care facilities within the European Union. The 1995 European Prevalence of Infection in Intensive Care (EPIC) study showed a 20.6% prevalence of ICU-acquired infection.
The prevalence of HAI among hospitalized patients in the US was 3.2% based on a survey in 2015, which was significantly lower than 4% in a study from 2011. The same study showed that among HAI in US health facilities, 36.4% were attributed to critical care locations, 57.5% in ward or nursery locations, 6.1% in step-down or specialty care units, or mixed acuity locations (different levels of acute care).
An earlier study showed the area of HAI acquisition was highest among adults and children outside ICU, ICU patients, high-risk neonate nurseries, and then well-baby nurseries. The estimated number of HAI in US hospitals in 2015 was 687,200, affecting 633,300 patients. These figures are promising compared to those in 2002, which determined the annual number of HAI in US hospitals at 1.7 million.
The endemic burden of HAI appears to be higher in developing countries. A pooled analysis of data from developing countries showed HAI prevalence of 15.5%, most of which occur as ventilator-associated pneumonia (VAP) and neonatal infections in intensive care settings. A systemic review of HAI in Southeast Asian countries found the overall prevalence to be 9.1%.
Routes of Transmission
Pathogens associated with healthcare-associated infection (HAI) may have different routes of transmission. The most common route of transmission is through contact, whereby the organisms are transmitted by direct or indirect contact. Common microorganisms that may be transmitted through contact are multidrug-resistant bacteria (such as MRSA, ESBL-producing Gram-negative organisms, VRE), C. difficile, and rotavirus. Droplet transmission may occur when microorganisms are transmitted from the respiratory tract by large droplets (greater than 5 microns) and travel less than 3 feet. Examples of infectious pathogens that are transmitted via the droplet route include influenza, Bordetella pertussis, and Neisseria meningitidis. Airborne transmission involves the transmission of organisms from the respiratory tract by small droplets (less than 5 microns) that travel long distances. Chickenpox virus, tuberculosis, measles, and the novel SARS-COV-2 virus may be transmitted through the airborne route.
Central Line-Associated Blood Stream Infection (CLABSI)
CLABSI occurs in the setting of a central venous line (CVC) and is the most preventable type of HAI. In the United States, 55% of ICU patients and 24% of non-ICU patients have CVC. CLABSI typically occurs when bacteria on the skin proliferate along the external portion of the catheter toward the intravascular part. Contamination of the CVC during insertion or manipulation process or by hematogenous seeding are other ways CLABSI can occur. Bacteria and fungal pathogens responsible for CLABSI and CAUTI frequently have virulence properties that result in biofilm production, which increases adherence and proliferation on external devices. A recent study in the United States listed the common organisms associated with CLABSI as S. aureus (23%), Candida species (13%), coagulase-negative Staphylococcus (12%), Enterococcus species (12%), Streptococcus species (12%), E.coli (8%), Bacteroides species (6%). However, other studies still show coagulase-negative Staphylococci as the most common organism. Among these pathogens, antimicrobial resistance is a serious problem.
Risk factors for CLABSI may be divided into host and catheter factors. Host factors include immunocompromised statuses such as chronic illness, neutropenia, malnutrition, parenteral nutrition, extremes of ages, and bone marrow transplantations. Catheter factors include prolonged hospitalization before catheterization, prolonged time of catheterization, multi-lumen CVC, type of catheter material, multiple CVC, urgent insertion, and lack of sterile barriers or breaks in the aseptic technique. There exists some debate about whether femoral CVC carries an increased risk of CLABSI as compared to subclavian or jugular sites.
Catheter-Associated Urinary tract Infection (CAUTI)
CAUTI is a urinary tract infection that occurs in the setting of an indwelling urinary catheter, which may be inserted for numerous medical indications. Approximately 15 to 25% of hospitalized patients in the United States have a urinary catheter. CAUTI can be classified as extraluminal or intraluminal. Extraluminal infections occur when bacteria track along the extraluminal surface of the catheter and enter from the urethral meatus to the bladder. Intraluminal infection arises when there is urinary stasis, usually due to blocked drainage or ascending infection from the intraluminal side of a contaminated catheter. Bacteria and fungal pathogens typically use biofilm formation to facilitate growth and spread along with the indwelling device. Fecal and skin microflora generally are the culprit pathogens. Numerous studies have listed E.coli as the most common CAUTI pathogen, followed by Klebsiella pneumonia/oxytoca, Enterococcus species, Pseudomonas aeruginosa, and Candida species. Complications of CAUTI include involvement of the upper urinary tract, sepsis, and bacteremia.
The most critical risk factor for CAUTI is the duration of catheterization. Operative or insertion protocol, such as nonadherence to aseptic techniques, is another modifiable risk factor. Patient characteristics that predispose to increased risk are female sex, paraplegia, cerebrovascular disease, older age, diabetes mellitus, history of UTI in the preceding year, and recent antibiotic use within 90 days.
Skin and Soft Tissue Infection (SSI)
SSI occurs in 2-5% of patients undergoing surgery and usually manifest within 30 days of surgery or 90 days of implanted devices. The infection depth and location determine the type of SSI: superficial SSI involves only the skin and subcutaneous tissues; deep SSI involves the muscle or facia, and organ or space-specific SSI occupy the anatomic vicinity of surgery. The patient’s skin, gastrointestinal tract, and female genital tract serve as a reservoir of the healthy flora that may contaminate the surgical site depending on the location of the surgery.
Procedure-related risk factors include the duration of surgery, wound class, hypothermia and hypovolemia during surgery, hypoxemia, the urgency of surgery, more than one intervention/surgery, necessity for blood transfusion, and the type of prosthesis implanted. The most critical risk factor is the duration of operation due to the time that the tissue is exposed to the environment leading to an increased chance of contamination.
The wound class is also an important consideration, dirty, contaminated, and clean-contaminated wounds have the greatest risk compared to clean wounds. Post-operative risk factors include the presence of wound drains, poor wound hygiene, and postoperative length of stay. Patient-related risk factors include immunosuppression, tobacco use, obesity, hyperglycemia, malnutrition, joint disease, and increasing age.
Common SSI pathogens are E.coli, S. aureus, Klebsiella species, Enterobacter species, Enterococcus species, Streptococcus species, Coagulase-negative Staphylococcus. Exogenous sources of microorganisms from surgical instrumentation, environment, and operator are less common sources and usually occur in clusters of infections.
Hospital-acquired pneumonia is pneumonia that develops after 48 hours of admission. Ventilator-associated pneumonia develops after 48 hours of endotracheal intubation. Approximately 5 to 15% of mechanically ventilated patients develop VAP.
Patients develop HAP as a result of aspiration, inhalation of contaminated aerosols, bacterial translocation, and via hematogenous spread. Pathogens commonly associated with HAP and VAP include S. aureus, P. aeruginosa, Candida species, Klebsiella oxytoca and pneumoniae, Streptococcus species, and Enterobacter species. Multi-drug resistant organisms are commonly seen in VAP. Host susceptibility depends on local factors, such as underlying lung disease, or systemic factors, such as immunosuppression, neutropenia, age greater than 70, dysphagia, and recent abdominal or thoracic surgery.
Mechanical ventilation, sedation, supine positioning, poor oral care, physical deconditioning, and reintubation are risk factors for VAP. Risk factors for developing HAP or VAP with multi-drug resistant organisms are prior IV antibiotic use within the last 90 days, need for ventilatory support, septic shock at the time of VAP, acute respiratory distress syndrome preceding VAP, more than five days of hospitalization before VAP onset and need for acute renal replacement therapy.
Clostridioides difficile Infection (CDI)
C. difficile is the single most common organism encountered in HAI. CDI causes antibiotic-associated diarrhea and colitis. Colonization of the intestinal tract occurs by fecal-oral transmission and also through aerosolization of spores. C. difficile produces toxins that act on intestinal epithelial cells leading to tissue injury and result in diarrhea. The most critical risk factor for healthcare-facility onset C. difficile infection (HO-CDI) is antibiotic use and environmental contamination, both of which are modifiable risk factors. Other frequently seen risk factors include increasing age, hospitalization, multiple comorbidities, use of gastric acid-suppressing medications, and immunosuppression.
Clinical manifestations vary depending on the type of healthcare-associated infection (HAI), implicated pathogen, and the severity of illness.
Central Line-Associated Blood Stream Infection (CLABSI) will manifest with fever and rigors due to bacteremia in a patient having a central line at the time of infection or within 48 hours after removal. Purulence or erythema at the site of insertion and catheter dysfunction may occur, but absence should not minimize suspicion of CLABSI. Occasionally complicated infections due to the bloodstream infection (BSI) may be the first manifestation, such as endocarditis, suppurative thrombophlebitis, septic arthritis, osteomyelitis, or abscess.
Catheter-Associated Urinary Tract Infection (CAUTI)
Signs and symptoms of CAUTIare similar to other urinary tract infections, but they occur with indwelling urethral or suprapubic catheters, intermittent catheterization, or within 48 hours of removal of a catheter. Common signs and symptoms are fever, suprapubic or costovertebral angle tenderness, acute hematuria, catheter obstruction, dysuria, urgency.
Skin and Soft Tissue Infection (SSI) will have different clinical signs and symptoms based on the site, type of infection, and pathogen(s) involved. SSI usually occurs within the first 30 days post-operatively or 90 days in the setting of prosthetic devices. Signs of inflammation, such as erythema, warmth, and pain, and wound dehiscence, are seen in SSI. Purulent drainage may be present depending on the characteristics of the implicated organism and typically occurs in superficial incisional infections. Post-surgical drains may also drain purulent material. Deep tissue and organ-specific/space occupying infections are usually somewhat concealed and present with more systemic signs, such as fevers, rigors, more profound and extensive pain, and leukocytosis.
Pneumonia will manifest with new-onset fever, cough, purulent sputum production, and declining oxygenation. To meet the criteria for HAP or VAP, the symptoms should have an onset after 48 hours of hospitalization or ventilation, respectively. Sedated patients on mechanical ventilation may present with fevers, increasing oxygen requirement, and purulent material from endotracheal suctioning. Physical examination findings may reveal coarse breath sounds and rales on auscultation, in the setting of parapneumonic effusions, there may be decreased breath sounds.
Healthcare Facility Onset C. difficile Infection (HO-CDI) should be suspected in the setting of unexplained CDI symptoms, which include three or more unformed stools in 24 hours that occur within three days of hospitalization. Diarrhea is the cardinal symptom of CDI. However, other signs and symptoms may include abdominal pain, distention, cramping, fever, nausea, anorexia, and dehydration. Symptoms typically occur in the setting of recent antibiotic use.
It is vital to consider immunocompromised and elderly patients who may not mount robust immune responses to infection. In these special patient populations, a high index of suspicion for underlying infection should be kept when there are signs of altered mental status, lethargy, fatigue, and changes in baseline vitals (tachycardia, hypotension, respiratory status).
In addition to the clinical manifestations and physical examination, laboratory and other diagnostic testing are used to confirm diagnoses of healthcare-associated infection (HAI). Routine blood tests, which include complete blood counts, metabolic panels, inflammatory markers, and blood gases will be useful to evaluate for HAI. Each type of HAI will require different workup, as indicated below.
Central Line-Associated Blood Stream Infection (CLABSI)
With the clinical suspicion of CLABSI, in the absence of other localized infection(s), blood cultures should be drawn. Ideally, samples for blood cultures should be drawn from two different sites, for example, one from CVC and the other from a peripheral vein before starting antibiotic therapy. Any purulent material at the exit site should be cultured.
Catheter-Associated Urinary Tract Infection (CAUTI)
Urine samples should be collected from a midstream sample after removal of the urinary catheter, if possible. This prevents the chances of obtaining bacteria present in the biofilms present on the walls of the catheter. Urinalysis and urine cultures should be obtained. Pyuria is commonly seen in catheterized patients with bacteriuria. Bacteriuria, with culture growth of 100,000 colony forming units (CFU)/mL of uropathogenic bacteria without UTI symptoms, is referred to as asymptomatic bacteriuria and is typically not treated. In patients with clinical manifestations of CAUTI not explained by another source of infection, and urine culture growth greater than 1,000 CFU/mL of one or more pathogens are diagnosed with CAUTI.
Skin and Soft Tissue Infection (SSI)
The clinical presentation should guide the evaluation of SSI. When an SSI is suspected, a sample of the infected tissue, drainage, or purulent material should be cultured with an antibiogram. Swabs may be done on deep wounds. However, superficial swabs may be contaminated with polymicrobial colonization. Different modalities of imaging may be used to identify organ or space-occupying SSI, especially to guide drainage of infected fluid or abscess.
Hospital-Acquired Pneumonia (HAP)/Ventilator Associated Pneumonia (VAP)
A clinical diagnosis of pneumonia should be further evaluated with radiography and microbiologic findings. A chest x-ray is most commonly used and may reveal new infiltrates. Leukocytosis or leukopenia may be present. Sputum samples should be obtained by non-invasive sampling from endotracheal aspiration or expectoration or via bronchoscopy with bronchoalveolar lavage or specimen brushing. Samples should be stained and cultured with antibiotic susceptibility testing. Depending on the clinical scenario, a specialized culture medium may be necessary to grow fastidious organisms, such as Mycobacterium tuberculosis or fungal pathogens.
C. difficile Infection (CDI)
Suspected CDI should be evaluated with stool tests for C. difficile toxin(s) or C. difficile toxin gene. Liquid stool from only clinically significant diarrhea should be sampled to limit false positives by highly sensitive diagnostic tests. A rectal swab may be done in patients with ileus and suspected CDI. Nucleic acid amplification testing (NAAT) is highly sensitive and may lead to overdiagnosis and overtreatment.
An algorithmic approach with initial enzyme immunoassay for toxins A and B and glutamate dehydrogenase antigen is recommended. Indeterminate toxin or antigen tests should be confirmed with the use of NAAT. Colonoscopy is not typically done for the sole purpose of diagnosing CDI. However, findings of pseudomembranous colitis are highly suggestive of CDI. Radiographic imaging may be warranted for patients with severe illness and suspected toxic megacolon or perforation.
Central Line-Associated Blood Stream Infection (CLABSI)
CVC catheter removal should be considered in specific circumstances and depending on the cultured organism. CVC infected with Candida, S. aureus, and Pseudomonas should be removed and replaced at an alternate site after subsequent blood cultures return negative. Antimicrobial therapy and duration are dictated by the specific organism that is cultured and severity of the infection. Further workup to evaluate for metastatic infections should be considered depending on the implicated organism and persistence of bacteremia after catheter removal. The second set of blood cultures should always be obtained to confirm clearance. Prevention of CLABSI is the best way to limit this type of HAI. Experienced operators should practice good hand hygiene, skin disinfection with chlorhexidine, and maintain aseptic techniques throughout the procedure. Interventions to mitigate the risk of CLABSI include daily review of CVC indication, minimizing the number of CVCs, and using only CVC with the required number of lumens.
Catheter-Associated Urinary Tract Infection (CAUTI)
Both catheter management and anti-microbial therapy are needed to treat CAUTI. Minimizing the use and duration of indwelling catheters is the most important preventive step. Daily assessment of indications and the need for continued catheterization should be done. Intermittent catheterization is associated with lower rates of CAUTI and should be considered in patients who definitely need it.
In the setting of CAUTI, removal of the urinary catheter is recommended after two weeks of use due to biofilm formation and inadequate response to antimicrobial therapy. Antimicrobial therapy should be based on cultures and susceptibility testing. Providers should use hospital or community antibiograms to direct initial treatment. There is no clear consensus on the use of antiseptic-coated urinary catheters or collection bags or antimicrobial catheter irrigation; in fact, there is suspicion that this may lead to increased antimicrobial resistance.
Skin and Soft Tissue Infection (SSI)
SSI is treated by debridement of devitalized tissue and drainage of infected fluids, including abscesses. Anti-microbial therapy should initially be chosen with broad coverage for the most common pathogens associated with the specific site of infection. Narrowing anti-microbial coverage should be guided by the culture results and the patient’s clinical picture, as the cultures may not always capture all the implicated pathogens in polymicrobial infections. Preventive measures for developing SSI may be broken down into pre-operative, intra-operative, and post-operative. Pre-operative preventative measures include reducing host-modifiable risk factors, administering pre-operative antibiotics if indicated, and de-colonization of specific pathogens. Hair removal is not usually necessary, and shaving the area may cause microtrauma and introduce bacteria more deep-seated in the epithelium. If hair removal is essential, hair should be clipped instead.
Intra-operative measures towards prevention include maintaining euthermia (temperature higher than 35.5 degrees Celsius), euvolemia, and avoiding hypoxemia, all of which are strategies to improve tissue oxygenation. Glycemic control should be achieved, keeping glucose concentrations less than 180mg/dL while avoiding hypoglycemia. Intra-operative antibiotics may be re-dosed as needed depending on the duration of surgery. Post-operative measures involve maintaining hygiene to the area, monitoring dressings, incision sites, post-operative drains. Prophylactic postoperative antibiotics may be indicated in dirty or contaminated wound, where there is already a presumed infection, or in immunocompromised patients.
The respiratory culture results should guide anti-microbial therapy for treating HAP and VAP. If a sample can not be obtained, empiric anti-microbial treatment should be started based on the hospital guidelines and hospital antibiograms for HAP and VAP. Patients should be reassessed daily for the need for continued anti-microbial therapy and depending on the level of suspicion of disease. Empiric treatment for VAP consists of coverage for P. aeroginosa, MRSA, and other gram-negative bacilli. Dual anti-pseudomonal coverage may be necessary based on patient risk factors and the hospital antibiogram to treat VAP.
In the setting of suspected aspiration pneumonia coverage for oral anaerobes should be started. Antibiotics should be de-escalated based on culture results and clinical stability of the patient. If symptoms don't improve within 72 hours or the patient is rapidly deteriorating after appropriate treatment is started, further investigation into complications or alternate sources of infection should be considered. Steps to prevent VAP pneumonia include limiting exposure to mechanical ventilation, decreasing the duration on the ventilator, titrating to low levels of effective sedation, and early mobilization.
C. difficile Infection (CDI)
Hospital-acquired CDI is treated similarly to community-acquired CDI. If the infection is associated with antibiotic use, the initial step is to discontinue the inciting antibiotic if feasible. Oral vancomycin, oral fidaxomicin, and metronidazole are active against C. difficile. Providers should follow the most recent guidelines for the treatment and management of CDI. Duration of therapy depends on concomitant antibiotic use, the severity of illness, recurrent disease. Surgical evaluation and fecal microbiota transplantation may be warranted in severe disease.
Prevention HO-CDI requires close surveillance of clustered outbreaks in healthcare facilities. Prevention strategies are targeted toward early detection, prompt isolation, and implementation of contact precautions, proper hand hygiene, environmental cleaning and disinfection, and anti-microbial stewardship.
The differential diagnoses of healthcare-associated infection (HAI) depend on the presenting symptoms, type of infection, and risk factors for developing a specific kind of infection. Differentiating a community-acquired infection versus one that is attributed to healthcare acquisition is essential because associated pathogens and anti-microbial resistance patterns differ between HAI and non-HAI.
Having a correct distinction between HAI and community-acquired infections guides the clinician to treat and manage the patient appropriately. For this reason, a careful review of symptom onset is essential. Different types of infections develop after a specific exposure, for example, broad-spectrum antibiotic use, presence of a CVC, or urinary catheter. The timing of symptoms can tell us if the infection was present before or after the specific intervention or hospitalization. In this way, many types of HAI can mimic the community-acquired version of the infection.
Central Line-Associated Blood Stream Infection (CLABSI): Bacteremia in the absence of CVC should be investigated and search for any underlying source that can produce bacteremia. If bacteremia develops in the setting of indwelling CVC, other causes of infection should be ruled out. Bacteremia may arise from a variety of sources, for example, wound infection, urinary tract infection, pneumonia, and endocarditis. The clinical presentation and timing of symptoms onset should be carefully evaluated, and symptoms should have started in the presence of a CVC or within 48 hours after removal.
Catheter-Associated Urinary Tract Infection (CAUTI): It is crucial to differentiate CAUTI from community-acquired urinary tract infection, the latter of which occurs in the absence of urinary catheter use. Urinary tract infections may present as lower urinary tract infections, such as acute cystitis or urethritis, or upper urinary tract infections, pyelonephritis, nephrolithiasis, and ureteritis.
Skin and Soft Tissue Infection (SSI): Post-operative fever may occur in atelectasis with pneumonia, urinary tract infection, medication side-effect, or drug reaction. Other localizing conditions may produce pain at the surgical site but are not necessarily considered SSI, such as wound dehiscence, wound herniation, cellulitis, burns, gas gangrene or myonecrosis, tumor or neoplastic process, and septic thrombophlebitis. SSI typically develop within 30 to 90 days after surgery. The diagnosis of SSI requires both clinical features of infection plus diagnostic criteria, such as purulent drainage, positive cultures, or radiographic imaging. The criteria vary depending on the class of infection.
Pneumonia: As with other HAI, the timing of onset of respiratory symptoms should guide the clinician to diagnose community-acquired versus hospital-acquired pneumonia. HAP will have a symptom onset after 48 hours of hospitalization or ventilation. The differential diagnosis for HAP is COPD, asthma, pulmonary edema, bronchiectasis, and pulmonary emboli. Upper respiratory tract infections may also mimic pneumonia symptoms. Differential diagnoses for VAP include acute respiratory distress syndrome, pneumonitis, pulmonary hemorrhage, pulmonary embolism, infiltrative tumor, and drug reaction.
Hospital-Acquired C. difficile Infection (HO-CDI): Symptoms of diarrhea should be differentiated between other infections or noninfectious causes. Antibiotic-associated diarrhea not associated with C. difficile, inflammatory bowel disease, irritable bowel syndrome, malabsorptive diarrhea, microscopic colitis are differential diagnoses of noninfectious causes of diarrhea. Infectious diarrhea may be associated with viral, fungal, or bacterial pathogens. Antibiotic-associated diarrhea may also be due to S. aureus, Salmonella, Bacteroides fragilis, Clostridium perfringens, or Klebsiella oxytoca. Acute abdomen associated with CDI can appear similar to ileus, colonic pseudo-obstruction, ischemia, or volvulus.
Other types of HAI outside of the five major groups of HAI, such as soft tissue, upper respiratory tract, central nervous system, and reproductive tract infections are less common but may occur. In general, any infection in which the symptoms begin after healthcare delivery may be attributed to HAI. The differential is broad and would mimic the community-acquired version of the infection.
The prognosis of healthcare-associated infection (HAI) varies on the type of HAI, the severity of illness, and the implicated pathogen. Worldwide morbidity and mortality are not well established due to limited surveillance and analysis. However, multiple studies over the years allow for estimates of the global burden of HAI. The mortality, length of stay, and associated costs associated with HAI are discussed below.
The exact mortality attributed to HAI worldwide is not known, but some studies show 30-day mortality around 10% in patients who acquired HAI. Others claim that the crude mortality rate associated with HAI varies from 12 to 80%, depending on the definition and populations under study. Excess mortality due to HAI seems to be greater in critically ill patients, even after accounting for admission prognostic factors and severity scores.
An international study showed that the ICU mortality rate of patients with HAI versus those without was 25% and 11%, respectively. This same study also showed that the overall hospital mortality rate was again doubled in patients with HAI versus those without, 30%, and 15%, respectively. The International Nosocomial Infection Control Consortium 2003-2008 report from ICUs in Latin America, Africa, Asia, and Europe showed crude excess mortality in adult patients of 29.3%, 23.6%, and 18.5% in VAP, CLABSI, and CAUTI respectively.
In 2002 the estimated deaths among US hospitals that were associated with HAI were 98,987 and varied by the type of infection: pneumonia (35,967), bloodstream infections (30,665), UTI (13,088), SSI (8,205), and other sites of infection (11,062).
Length of Hospital Stay
Analysis of surveillance models in a German hospital showed that additional length of hospital stay (LOS) was sensitive to the location of acquisition and the type of HAI. The extra LOS due to all HAI was 12 days for all units but differed on the type of HAI such that CAUTI, SSI, and primary bloodstream infections were responsible for 3.3, 12.9, and 12.5 additional days, respectively. Having multiple HAIs in the same patient prolonged extra LOS to 25.6 days. The LOS in patients with and without HAI was 26.30 and 5.69 days in a US hospital, respectively. The additional LOS due to HAI in developing countries was reported between 5 to 23 days.
The annual costs of the five major types of HAI occurring in acute care hospitals are estimated to be $9.8 billion in US adult inpatient populations alone. The most costly HAI are listed in the following order, along with the respective contributing percentages: SSI (33.7%), VAP (31.7%), CLABSI (18.9%), CDI (15.4%) and CAUTI (0.3%). The CDC estimates that all HAI cost the US healthcare system from $28 billion to $45 billion annually. In Europe, HAI-associated costs are approximately € 7 billion annually.
Complications of healthcare-associated infection (HAI) are broad and depend on the type of infection, the severity of illness, and implicated pathogen. The list of complications of each type of HAI can be extensive, below a few of the more common complications of each HAI are listed.
Complications of Hospital Acquired Pneumonia (HAP)/Ventilator Associated Pneumonia (VAP)
Complications of Central Line-Associated Blood Stream Infection (CLABSI)
Complications of Catheter-Associated Urinary Tract Infection (CAUTI)
Complications of Skin and Soft Tissue Infection (SSI)
Complications of Hospital Acquired C. difficile Infection (HO-CDI)
Hand hygiene is the most important aspect of infection control and prevention of healthcare-associated infection (HAI). Pathogenic microorganisms that are transiently on the healthcare worker are readily removed with routine hand hygiene and limit the risk of transmission to the patient. Hand hygiene also prevents colonization and infection in the healthcare worker and the contamination of the environment. The World Health Organization has identified five moments in which hand hygiene should always be practiced:
Alcohol-based hand sanitizers are preferred over soap and water washing except when hands are visibly soiled, contact with body fluids after using the toilet, or there is exposure to spore-forming pathogens such as C. difficile. Studies have shown that complying to hand hygiene recommendations reduces the pathogen load, prevents transmission of HAI.
Standard precautions should be practiced to protect healthcare workers. This includes the use of personal protective equipment such as gloves, gowns, masks, and eye protection to protect from blood and body fluids. Transmission based precautions should be used to prevent airborne, droplet, and contact transmission. A fit-tested N-95 respirator should be worn and patient placement in an isolated negative pressure room to prevent airborne transmission. Surgical masks and physical distancing are precautions to prevent droplet transmission. Patient placement in a single room and healthcare worker gown and gloves are worn to avoid contact transmission of MDRO and C. difficile. Aseptic techniques should be practiced for invasive procedures and surgery.
Environmental contamination is a potential source of pathogens that may be transmitted through contact. One study found that hospital water taps, door handles, and working surfaces had the highest number of microbes. Patient equipment and environment are potential sources and should be kept clean. Hospital waste often acts as a reservoir for pathogenic bacteria.
Estimates are that 20 to 25% of hospital waste was high potential to cause HAI, and care should be given to ensure appropriate handling and disposal. Given the high potential for bacterial transmission from environmental sources, monitoring and enforcing appropriate cleaning regimens are recommended to prevent HAI.
Antimicrobial stewardship involves monitoring appropriate antimicrobial use and antibiotic resistance and implementing antibiotic control policies. Millions of antibiotic prescriptions are prescribed to patients each year during office visits, but it is estimated that approximately 50% of these are not necessary. Overuse of antibiotics not only places patients at risk for developing medication side effects and CDI but also contributes to the heightening problem of antimicrobial resistance.
Patients should be informed about the potential risk of developing HAI when receiving care. Healthcare workers should assess the patient's risk factors for developing a specific infection and identify and address ways to limit modifiable risk factors. Patients with modifiable risk factors should be educated on ways that they can reduce their risk of developing HAI. For example, smoking habits, cleaning, and not shaving the area before a surgical procedure can reduce SSI. Providers should be careful and cautious with the use of devices and the need for invasive interventions. Patients should be educated on appropriate antibiotic use and indications to prevent potential antibiotic misuse.
At one time, healthcare-associated infection (HAI) was viewed as an unavoidable risk of care. Systematic reviews of healthcare epidemiology in US hospitals has shown that 100% prevention of HAI may not be achievable. However, 65-70% of CLABSI and CAUTI and 55% of VAP and SSI may be preventable with infection prevention strategies. Due to the growing effort of infection prevention and control programs, we have seen improvements in the number of HAIs and a shift in the types of HAI most commonly encountered. Progress towards the elimination of HAI is the goal of healthcare teams. Efforts are being made by the World Health Organization to implement infection prevention and control programs and better surveillance systems in developing countries to reduce HAI.
Infection prevention and control programs are rooted in quality improvement activities that use protocols and interventions to decrease the risk of acquisition and transmission of infection within healthcare settings. Infection prevention teams work with healthcare providers and staff to develop, implement, and monitor protocols and interventions that aim to limit HAI. Education of healthcare providers, hand hygiene, cleaning and disinfecting medical equipment, environmental contamination prevention, isolation precautions, and surveillance of data analysis are examples of such interventions. These interventions should start with staff who are directly in contact with the patients, such as nurses, providers, medical technicians, and environmental service staff.
Pharmacists may be involved through the monitoring of antimicrobial stewardship programs to limit inappropriate antibiotic use and help to prevent resistant pathogens. Laboratory technicians can help with keeping track of antibiograms and susceptibility patterns to facilitate antibiotic stewardship programs.[Level 4]
Studies have shown that implementing infection prevention and control programs can reduce the length of stay and avoid additional costs. It is estimated that hospitals can avoid between 12,000 to 223,000 HAIs and save $142 million to $4.25 billion annually with infection prevention measures.
Most recent studies show a pay-off for healthcare systems to adopting HAI reduction programs. A study from 2015 to 2018 showed that the hospital cost of eliminating one HAI was $25,008. However, the profit was $582,464, which is highly encouraging to a hospital management perspective that reduction of HAI is profitable to hospitals. The elimination of HAIs allows for a shorter hospital course, which allows for a higher capacity of admissions, which makes the funding of HAI reduction programs profitable from an administrative standpoint.[Level 4]
With the growing body of evidence for monitoring HAI within the United States, the prevalence has significantly decreased in the last decade. Specifically, the prevention of SSI and CAUTI had the greatest success. This success is rooted in quality improvement initiatives for reducing SSI and CAUTI. The prevalence of pneumonia and CDI had little change in prevalence. This addresses a need for continued improvement in infection prevention and control programs. HAP, particularly NV-HAP, requires more attention and prevention efforts.
A recent model showed that the prevention of NV-HAP by 50% could save 9,886 lives, 487,622 additional hospital days, and $2.43 billion annually, resulting in significantly decreased morbidity, mortality, and financial burden. Another avenue for improvement would be better surveillance programs for monitoring HAI in long term care facilities in the United States, of which there is little data available.
|||Magill SS,O'Leary E,Janelle SJ,Thompson DL,Dumyati G,Nadle J,Wilson LE,Kainer MA,Lynfield R,Greissman S,Ray SM,Beldavs Z,Gross C,Bamberg W,Sievers M,Concannon C,Buhr N,Warnke L,Maloney M,Ocampo V,Brooks J,Oyewumi T,Sharmin S,Richards K,Rainbow J,Samper M,Hancock EB,Leaptrot D,Scalise E,Badrun F,Phelps R,Edwards JR, Changes in Prevalence of Health Care-Associated Infections in U.S. Hospitals. The New England journal of medicine. 2018 Nov 1; [PubMed PMID: 30380384]|
|||Suetens C,Latour K,Kärki T,Ricchizzi E,Kinross P,Moro ML,Jans B,Hopkins S,Hansen S,Lyytikäinen O,Reilly J,Deptula A,Zingg W,Plachouras D,Monnet DL, Prevalence of healthcare-associated infections, estimated incidence and composite antimicrobial resistance index in acute care hospitals and long-term care facilities: results from two European point prevalence surveys, 2016 to 2017. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2018 Nov; [PubMed PMID: 30458912]|
|||Allegranzi B,Bagheri Nejad S,Combescure C,Graafmans W,Attar H,Donaldson L,Pittet D, Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis. Lancet (London, England). 2011 Jan 15; [PubMed PMID: 21146207]|
|||Storr J,Twyman A,Zingg W,Damani N,Kilpatrick C,Reilly J,Price L,Egger M,Grayson ML,Kelley E,Allegranzi B, Core components for effective infection prevention and control programmes: new WHO evidence-based recommendations. Antimicrobial resistance and infection control. 2017; [PubMed PMID: 28078082]|
|||Magill SS,Edwards JR,Bamberg W,Beldavs ZG,Dumyati G,Kainer MA,Lynfield R,Maloney M,McAllister-Hollod L,Nadle J,Ray SM,Thompson DL,Wilson LE,Fridkin SK, Multistate point-prevalence survey of health care-associated infections. The New England journal of medicine. 2014 Mar 27; [PubMed PMID: 24670166]|
|||Ewan VC,Witham MD,Kiernan M,Simpson AJ, Hospital-acquired pneumonia surveillance-an unmet need. The Lancet. Respiratory medicine. 2017 Oct; [PubMed PMID: 28781029]|
|||Falagas ME,Kopterides P,Siempos II, Attributable mortality of Acinetobacter baumannii infection among critically ill patients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2006 Aug 1; [PubMed PMID: 16804863]|
|||Vincent JL,Rello J,Marshall J,Silva E,Anzueto A,Martin CD,Moreno R,Lipman J,Gomersall C,Sakr Y,Reinhart K, International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009 Dec 2; [PubMed PMID: 19952319]|
|||Jernigan JA,Hatfield KM,Wolford H,Nelson RE,Olubajo B,Reddy SC,McCarthy N,Paul P,McDonald LC,Kallen A,Fiore A,Craig M,Baggs J, Multidrug-Resistant Bacterial Infections in U.S. Hospitalized Patients, 2012-2017. The New England journal of medicine. 2020 Apr 2; [PubMed PMID: 32242356]|
|||Sievert DM,Ricks P,Edwards JR,Schneider A,Patel J,Srinivasan A,Kallen A,Limbago B,Fridkin S, Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infection control and hospital epidemiology. 2013 Jan; [PubMed PMID: 23221186]|
|||Spivak ES,Hanson KE, Candida auris: an Emerging Fungal Pathogen. Journal of clinical microbiology. 2018 Feb; [PubMed PMID: 29167291]|
|||Weiner LM,Webb AK,Limbago B,Dudeck MA,Patel J,Kallen AJ,Edwards JR,Sievert DM, Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014. Infection control and hospital epidemiology. 2016 Nov; [PubMed PMID: 27573805]|
|||Park JH,Ryu SH,Lee JY,Kim HJ,Kwak SH,Jung J,Lee J,Sung H,Kim SH, Airborne fungal spores and invasive aspergillosis in hematologic units in a tertiary hospital during construction: a prospective cohort study. Antimicrobial resistance and infection control. 2019; [PubMed PMID: 31161035]|
|||Lemaire B,Normand AC,Forel JM,Cassir N,Piarroux R,Ranque S, Hospitalized Patient as Source of Aspergillus fumigatus, 2015. Emerging infectious diseases. 2018 Aug; [PubMed PMID: 30014836]|
|||Aitken C,Jeffries DJ, Nosocomial spread of viral disease. Clinical microbiology reviews. 2001 Jul; [PubMed PMID: 11432812]|
|||Ganczak M,Barss P, Nosocomial HIV infection: epidemiology and prevention--a global perspective. AIDS reviews. 2008 Jan-Mar; [PubMed PMID: 18385780]|
|||Vincent JL,Bihari DJ,Suter PM,Bruining HA,White J,Nicolas-Chanoin MH,Wolff M,Spencer RC,Hemmer M, The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA. 1995 Aug 23-30; [PubMed PMID: 7637145]|
|||Klevens RM,Edwards JR,Richards CL Jr,Horan TC,Gaynes RP,Pollock DA,Cardo DM, Estimating health care-associated infections and deaths in U.S. hospitals, 2002. Public health reports (Washington, D.C. : 1974). 2007 Mar-Apr; [PubMed PMID: 17357358]|
|||Ling ML,Apisarnthanarak A,Madriaga G, The Burden of Healthcare-Associated Infections in Southeast Asia: A Systematic Literature Review and Meta-analysis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2015 Jun 1; [PubMed PMID: 25676799]|
|||Ferioli M,Cisternino C,Leo V,Pisani L,Palange P,Nava S, Protecting healthcare workers from SARS-CoV-2 infection: practical indications. European respiratory review : an official journal of the European Respiratory Society. 2020 Mar 31; [PubMed PMID: 32248146]|
|||Climo M,Diekema D,Warren DK,Herwaldt LA,Perl TM,Peterson L,Plaskett T,Price C,Sepkowitz K,Solomon S,Tokars J,Fraser VJ,Wong E, Prevalence of the use of central venous access devices within and outside of the intensive care unit: results of a survey among hospitals in the prevention epicenter program of the Centers for Disease Control and Prevention. Infection control and hospital epidemiology. 2003 Dec; [PubMed PMID: 14700410]|
|||Bell T,O'Grady NP, Prevention of Central Line-Associated Bloodstream Infections. Infectious disease clinics of North America. 2017 Sep; [PubMed PMID: 28687213]|
|||Baier C,Linke L,Eder M,Schwab F,Chaberny IF,Vonberg RP,Ebadi E, Incidence, risk factors and healthcare costs of central line-associated nosocomial bloodstream infections in hematologic and oncologic patients. PloS one. 2020; [PubMed PMID: 31978169]|
|||Hooton TM,Bradley SF,Cardenas DD,Colgan R,Geerlings SE,Rice JC,Saint S,Schaeffer AJ,Tambayh PA,Tenke P,Nicolle LE, Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2010 Mar 1; [PubMed PMID: 20175247]|
|||Letica-Kriegel AS,Salmasian H,Vawdrey DK,Youngerman BE,Green RA,Furuya EY,Calfee DP,Perotte R, Identifying the risk factors for catheter-associated urinary tract infections: a large cross-sectional study of six hospitals. BMJ open. 2019 Feb 21; [PubMed PMID: 30796114]|
|||Isikgoz Tasbakan M,Durusoy R,Pullukcu H,Sipahi OR,Ulusoy S, Hospital-acquired urinary tract infection point prevalence in Turkey: differences in risk factors among patient groups. Annals of clinical microbiology and antimicrobials. 2013 Nov 4; [PubMed PMID: 24188193]|
|||Anderson DJ,Podgorny K,Berríos-Torres SI,Bratzler DW,Dellinger EP,Greene L,Nyquist AC,Saiman L,Yokoe DS,Maragakis LL,Kaye KS, Strategies to prevent surgical site infections in acute care hospitals: 2014 update. Infection control and hospital epidemiology. 2014 Sep; [PubMed PMID: 25376070]|
|||Mukagendaneza MJ,Munyaneza E,Muhawenayo E,Nyirasebura D,Abahuje E,Nyirigira J,Harelimana JD,Muvunyi TZ,Masaisa F,Byiringiro JC,Hategekimana T,Muvunyi CM, Incidence, root causes, and outcomes of surgical site infections in a tertiary care hospital in Rwanda: a prospective observational cohort study. Patient safety in surgery. 2019; [PubMed PMID: 30820247]|
|||Mioton LM,Jordan SW,Hanwright PJ,Bilimoria KY,Kim JY, The Relationship between Preoperative Wound Classification and Postoperative Infection: A Multi-Institutional Analysis of 15,289 Patients. Archives of plastic surgery. 2013 Sep; [PubMed PMID: 24086804]|
|||Gibbons C,Bruce J,Carpenter J,Wilson AP,Wilson J,Pearson A,Lamping DL,Krukowski ZH,Reeves BC, Identification of risk factors by systematic review and development of risk-adjusted models for surgical site infection. Health technology assessment (Winchester, England). 2011 Sep; [PubMed PMID: 21884656]|
|||Klompas M,Branson R,Eichenwald EC,Greene LR,Howell MD,Lee G,Magill SS,Maragakis LL,Priebe GP,Speck K,Yokoe DS,Berenholtz SM, Strategies to prevent ventilator-associated pneumonia in acute care hospitals: 2014 update. Infection control and hospital epidemiology. 2014 Sep; [PubMed PMID: 25376073]|
|||Komiya K,Ishii H,Kadota J, Healthcare-associated Pneumonia and Aspiration Pneumonia. Aging and disease. 2015 Feb; [PubMed PMID: 25657850]|
|||Kózka M,Sega A,Wojnar-Gruszka K,Tarnawska A,Gniadek A, Risk Factors of Pneumonia Associated with Mechanical Ventilation. International journal of environmental research and public health. 2020 Jan 19; [PubMed PMID: 31963947]|
|||Kumar ST,Yassin A,Bhowmick T,Dixit D, Recommendations From the 2016 Guidelines for the Management of Adults With Hospital-Acquired or Ventilator-Associated Pneumonia. P [PubMed PMID: 29234216]|
|||Roberts K,Smith CF,Snelling AM,Kerr KG,Banfield KR,Sleigh PA,Beggs CB, Aerial dissemination of Clostridium difficile spores. BMC infectious diseases. 2008 Jan 24; [PubMed PMID: 18218089]|
|||Loo VG,Bourgault AM,Poirier L,Lamothe F,Michaud S,Turgeon N,Toye B,Beaudoin A,Frost EH,Gilca R,Brassard P,Dendukuri N,Béliveau C,Oughton M,Brukner I,Dascal A, Host and pathogen factors for Clostridium difficile infection and colonization. The New England journal of medicine. 2011 Nov 3; [PubMed PMID: 22047560]|
|||Papazian L,Klompas M,Luyt CE, Ventilator-associated pneumonia in adults: a narrative review. Intensive care medicine. 2020 Mar 10; [PubMed PMID: 32157357]|
|||Polage CR,Gyorke CE,Kennedy MA,Leslie JL,Chin DL,Wang S,Nguyen HH,Huang B,Tang YW,Lee LW,Kim K,Taylor S,Romano PS,Panacek EA,Goodell PB,Solnick JV,Cohen SH, Overdiagnosis of Clostridium difficile Infection in the Molecular Test Era. JAMA internal medicine. 2015 Nov; [PubMed PMID: 26348734]|
|||Madden GR,Poulter MD,Sifri CD, Diagnostic stewardship and the 2017 update of the IDSA-SHEA Clinical Practice Guidelines for Clostridium difficile Infection. Diagnosis (Berlin, Germany). 2018 Sep 25; [PubMed PMID: 29990306]|
|||Lutwick L,Al-Maani AS,Mehtar S,Memish Z,Rosenthal VD,Dramowski A,Lui G,Osman T,Bulabula A,Bearman G, Managing and preventing vascular catheter infections: A position paper of the international society for infectious diseases. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2019 Jul [PubMed PMID: 31005622]|
|||Bratzler DW,Dellinger EP,Olsen KM,Perl TM,Auwaerter PG,Bolon MK,Fish DN,Napolitano LM,Sawyer RG,Slain D,Steinberg JP,Weinstein RA, Clinical practice guidelines for antimicrobial prophylaxis in surgery. Surgical infections. 2013 Feb; [PubMed PMID: 23461695]|
|||Dinleyici M,Vandenplas Y, Clostridium difficile Colitis Prevention and Treatment. Advances in experimental medicine and biology. 2019; [PubMed PMID: 30689174]|
|||Polage CR,Solnick JV,Cohen SH, Nosocomial diarrhea: evaluation and treatment of causes other than Clostridium difficile. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2012 Oct; [PubMed PMID: 22700831]|
|||Koch AM,Nilsen RM,Eriksen HM,Cox RJ,Harthug S, Mortality related to hospital-associated infections in a tertiary hospital; repeated cross-sectional studies between 2004-2011. Antimicrobial resistance and infection control. 2015; [PubMed PMID: 26719795]|
|||Kanerva M,Ollgren J,Virtanen MJ,Lyytikäinen O, Risk factors for death in a cohort of patients with and without healthcare-associated infections in Finnish acute care hospitals. The Journal of hospital infection. 2008 Dec; [PubMed PMID: 18951660]|
|||Vincent JL, Nosocomial infections in adult intensive-care units. Lancet (London, England). 2003 Jun 14; [PubMed PMID: 12814731]|
|||Soufir L,Timsit JF,Mahe C,Carlet J,Regnier B,Chevret S, Attributable morbidity and mortality of catheter-related septicemia in critically ill patients: a matched, risk-adjusted, cohort study. Infection control and hospital epidemiology. 1999 Jun; [PubMed PMID: 10395140]|
|||Rosenthal VD,Maki DG,Jamulitrat S,Medeiros EA,Todi SK,Gomez DY,Leblebicioglu H,Abu Khader I,Miranda Novales MG,Berba R,Ramírez Wong FM,Barkat A,Pino OR,Dueñas L,Mitrev Z,Bijie H,Gurskis V,Kanj SS,Mapp T,Hidalgo RF,Ben Jaballah N,Raka L,Gikas A,Ahmed A,Thu le TA,Guzmán Siritt ME, International Nosocomial Infection Control Consortium (INICC) report, data summary for 2003-2008, issued June 2009. American journal of infection control. 2010 Mar; [PubMed PMID: 20176284]|
|||Arefian H,Hagel S,Fischer D,Scherag A,Brunkhorst FM,Maschmann J,Hartmann M, Estimating extra length of stay due to healthcare-associated infections before and after implementation of a hospital-wide infection control program. PloS one. 2019; [PubMed PMID: 31100094]|
|||Shepard J,Frederick J,Wong F,Madison S,Tompkins L,Hadhazy E, Could the prevention of health care-associated infections increase hospital cost? The financial impact of health care-associated infections from a hospital management perspective. American journal of infection control. 2020 Mar; [PubMed PMID: 32089192]|
|||Esatoğlu AE,Agirbas I,Onder OR,Celik Y, Additional cost of hospital-acquired infection to the patient: a case study in Turkey. Health services management research. 2006 Aug; [PubMed PMID: 16848954]|
|||Zimlichman E,Henderson D,Tamir O,Franz C,Song P,Yamin CK,Keohane C,Denham CR,Bates DW, Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system. JAMA internal medicine. 2013 Dec 9-23; [PubMed PMID: 23999949]|
|||Mathai E,Allegranzi B,Kilpatrick C,Pittet D, Prevention and control of health care-associated infections through improved hand hygiene. Indian journal of medical microbiology. 2010 Apr-Jun; [PubMed PMID: 20404452]|
|||Pittet D,Allegranzi B,Sax H,Dharan S,Pessoa-Silva CL,Donaldson L,Boyce JM, Evidence-based model for hand transmission during patient care and the role of improved practices. The Lancet. Infectious diseases. 2006 Oct; [PubMed PMID: 17008173]|
|||Allegranzi B,Pittet D, Role of hand hygiene in healthcare-associated infection prevention. The Journal of hospital infection. 2009 Dec; [PubMed PMID: 19720430]|
|||Tagoe DN,Desbordes KK, Investigating potential sources of transmission of healthcare-associated infections in a regional hospital, Ghana. International journal of applied [PubMed PMID: 23776803]|
|||Bagheri Nejad S,Allegranzi B,Syed SB,Ellis B,Pittet D, Health-care-associated infection in Africa: a systematic review. Bulletin of the World Health Organization. 2011 Oct 1; [PubMed PMID: 22084514]|
|||Colgan R,Powers JH, Appropriate antimicrobial prescribing: approaches that limit antibiotic resistance. American family physician. 2001 Sep 15; [PubMed PMID: 11578036]|
|||Weiner LM,Fridkin SK,Aponte-Torres Z,Avery L,Coffin N,Dudeck MA,Edwards JR,Jernigan JA,Konnor R,Soe MM,Peterson K,McDonald LC, Vital Signs: Preventing Antibiotic-Resistant Infections in Hospitals - United States, 2014. MMWR. Morbidity and mortality weekly report. 2016 Mar 11; [PubMed PMID: 26963489]|
|||Umscheid CA,Mitchell MD,Doshi JA,Agarwal R,Williams K,Brennan PJ, Estimating the proportion of healthcare-associated infections that are reasonably preventable and the related mortality and costs. Infection control and hospital epidemiology. 2011 Feb; [PubMed PMID: 21460463]|
|||Yokoe DS,Anderson DJ,Berenholtz SM,Calfee DP,Dubberke ER,Ellingson KD,Gerding DN,Haas JP,Kaye KS,Klompas M,Lo E,Marschall J,Mermel LA,Nicolle LE,Salgado CD,Bryant K,Classen D,Crist K,Deloney VM,Fishman NO,Foster N,Goldmann DA,Humphreys E,Jernigan JA,Padberg J,Perl TM,Podgorny K,Septimus EJ,VanAmringe M,Weaver T,Weinstein RA,Wise R,Maragakis LL, A compendium of strategies to prevent healthcare-associated infections in acute care hospitals: 2014 updates. Infection control and hospital epidemiology. 2014 Sep; [PubMed PMID: 25376067]|
|||Schmier JK,Hulme-Lowe CK,Semenova S,Klenk JA,DeLeo PC,Sedlak R,Carlson PA, Estimated hospital costs associated with preventable health care-associated infections if health care antiseptic products were unavailable. ClinicoEconomics and outcomes research : CEOR. 2016; [PubMed PMID: 27257390]|
|||Baker D,Quinn B, Hospital Acquired Pneumonia Prevention Initiative-2: Incidence of nonventilator hospital-acquired pneumonia in the United States. American journal of infection control. 2018 Jan; [PubMed PMID: 29050903]|